Faruqi & Faruqi Investigation: ZS Pharma, Inc.

Faruqi & Faruqi, LLP Announces the Investigation of ZS Pharma, Inc. (ZSPH) Over the Proposed Sale of the Company to AstraZeneca PLC

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ZS Pharma, Inc. (“ZS” or the “Company”) (NasdaqGM:ZSPH) for potential breaches of fiduciary duties in connection with the sale of the Company to AstraZeneca PLC for approximately $2.7 billion.
The Company’s stockholders will only receive $90.00 in cash for each share of Company common stock they own. However, the offer is below at least one analyst’s target price of $110.00 per share.
If you own common stock in ZS and wish to obtain additional information and protect your investments free of charge, please contact Juan Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Logo Twitter Facebook LinkedIn Google+